Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Biopsy Clear all
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions
Tagraxofusp, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

NCT04807868
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Standard of care liver biopsy, Fibroscan, Biospecimen Collection
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 10, 2026, 9:44 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

NCT05687188
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Blood Sample Collection, Tissue Sample Collection, Data Collection, Medical Image Collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 10, 2026, 9:44 PM EDT
Terminated Not applicable Interventional Results available

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

NCT02501759
View directory record Official record
Conditions
Health Status Unknown, Prostate Carcinoma
Interventions
3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging, Transrectal Biopsy, Ultrasound-Guided Prostate Biopsy
Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 10, 2026, 9:44 PM EDT
Completed Not applicable Interventional Results available

Optoacoustic Images Versus Imagio® Ultrasound

NCT04030104
View directory record Official record
Conditions
Breast Cancer
Interventions
Reader Study - Imagio Ultrasound, Reader Study Imagio Ultrasound + Optoacoustic Imaging, Mammography
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 10, 2026, 9:44 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

NCT05574114
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
Interventions
Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product
Radiation · Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 10, 2026, 9:44 PM EDT
Active, not recruiting Phase 2 Interventional

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT04462406
View directory record Official record
Conditions
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
482
States / cities
Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting No phase listed Observational

Quantitative MRI for Myelofibrosis

NCT01973881
View directory record Official record
Conditions
Myelofibrosis
Interventions
T1 Weighted MRI (magnetic resonance imaging)
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Terminated Phase 1 Interventional

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

NCT02111824
View directory record Official record
Conditions
Lung Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases
Interventions
MIMIG System, Indocyanine Green (ICG)
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 10, 2026, 9:44 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy

NCT02610621
View directory record Official record
Conditions
Breast Cancer
Interventions
Lumpectomy without sentinel node biopsy
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 10, 2026, 9:44 PM EDT
Not listed Phase 4 Interventional

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

NCT00999258
View directory record Official record
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2009 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Completed Not applicable Interventional

Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

NCT02406274
View directory record Official record
Conditions
Breast Abnormalities
Interventions
Contrast Enhanced Spectral Mammography (CESM)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 10, 2026, 9:44 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Recruiting Phase 2 Interventional

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

NCT06492759
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Not listed No phase listed Observational

Amyloidosis Incidence in High-Risk Cardiac Device Patients

NCT06186167
View directory record Official record
Conditions
Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
Interventions
Chest Wall Fat Tissue Collection
Procedure
Lead sponsor
Midwest Heart & Vascular Specialists
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 10, 2026, 9:44 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Health eHeart BioBank

NCT06976502
View directory record Official record
Conditions
Heart Diseases, Cardiac Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Blood Draw, Tissue Collection, DNA Collection, Medical Chart Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Completed No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 10, 2026, 9:44 PM EDT
Completed Phase 1 Interventional

Trial of eRapa in Prostate Cancer Patients

NCT03618355
View directory record Official record
Conditions
Prostate Cancer
Interventions
eRapa (encapsulated rapamycin)
Drug
Lead sponsor
Rapamycin Holdings, Inc. dba Emtora Biosciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 10, 2026, 9:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound-Related Scientific Study

NCT00759889
View directory record Official record
Conditions
Diabetic Foot, Leg Ulcer, Decubitus Ulcer
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 10, 2026, 9:44 PM EDT